度普利尤单抗治疗老年痒疹型特应性皮炎的临床疗效与安全性  

Clinical effectiveness of dupilumab for the treatment of prurigo phenotype of atopic dermatitis in the elderly

作　　者：窦越 初高平 王静[1] 马光辉 马蕾[1] DOU Yue;CHU Gaoping;WANG Jing;MA Guanghui;MA Lei(Department of Dermatology,Binzhou Medical University Hospital,Binzhou 256603,Shandong,P.R.China)

机构地区：[1]滨州医学院附属医院皮肤科,山东滨州256603

出　　处：《滨州医学院学报》2025年第1期22-25,共4页Journal of Binzhou Medical University

摘　　要：目的评价度普利尤单抗治疗老年痒疹型特应性皮炎的临床疗效与安全性。方法分析接受度普利尤单抗规范治疗16周的36例老年痒疹型特应性皮炎患者的临床资料。记录治疗前、治疗第2、4、6、8、12、16周患者峰值瘙痒数字评价量表(peak pruritus numeric rating scale,PP-NRS)评分、特应性皮炎视觉模拟量表失眠评分(SCORAD sleep loss VAS score)、皮肤病生活质量指数(dermatology life quality index,DLQI)评分以及研究者总体评估(investigator′s global assessment,IGA)评分,比较治疗后各观察时间点之间及与治疗前的评分差异,观察并记录不良反应。评价治疗16周达到IGA0/1级、IGA0级以及PP-NRS降低至少4分(PP-NRS4)的患者比例。结果度普利尤单抗治疗16周时,PP-NRS、SCORAD sleep loss VAS score、DLQI及IGA均较治疗前显著降低,差异均具有统计学意义(P均<0.05)。除IGA治疗2周与治疗前、DLQI治疗8周与治疗6周、特应性皮炎视觉模拟量表失眠评分治疗16周与治疗12周比较无统计学差异外,所有四项观察指标在不同治疗时间点之间比较差异均具有统计学意义(P均<0.05)。16周时,达到IGA 0/1级、IGA0级和PP-NRS4的患者比例分别是52.78%、25%和72.2%。治疗过程中仅2例患者在治疗4周时出现轻度结膜炎,给予对症处理后明显好转。结论度普利尤单抗治疗老年痒疹型特应性皮炎具有良好的疗效与安全性。Objective To evaluate the clinical effectiveness and safety of dupilumab for the treatment of prurigo phenotype of atopic dermatitis(AD)in the elderly.Methods A retrospective study was conducted to analyze the clinical data of 36 elder patients with prurigo phenotype of AD who received the standardized treatment with dupilumab for 16 weeks.The scores of Peak Pruritus Numeric Rating Scale(PP-NRS),SCORAD sleep loss VAS,Dermatology Life Quality Index(DLQI)and Investigator′s Global Assessment(IGA)were recorded and compared before the treatment and at 2nd,4th,6th,8th,12th and 16th weeks after the treatment.The scores were compared between observation time points after the treatment and before the treatment,and adverse reactions were observed and recorded.The percentages of patients achieving IGA0/1,IGA0 and PP-NRS4 were calculated.At the same time,adverse reactions were recorded during treatment.Results At the 16th week,the patients′scores of PP-NRS,SCORAD sleep loss VAS,DLQI and IGA were all obviously decreased compared with those before the treatment(all P<0.05).Except for the differences between IGA scores of the 2nd week and before the treatment,DLQI scores of the 8th week and 6th week,SCORAD sleep loss VAS scores of 16th week and 12th week,there were all statistically significant differences between each two time-points among the four observed indicators(all P<0.05).At the 16th week,the percentages of patients achieving IGA0/1,IGA0 and PP-NRS4 were 52.78%,25%and 72.2%respectively.In the course of the treatment,only 2 patients developed mild conjunctivitis at 4th week of the treatment,and significantly improved after the symptomatic treatment.Conclusion Dupilumab is markedly effective and safe for the treatment of elder prurigo phenotype of atopic dermatitis.

关 键 词：老年人 痒疹 皮炎 特应性 度普利尤单抗 疗效 安全性 

分 类 号：R758.2[医药卫生—皮肤病学与性病学]